FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4300890579> ?p ?o ?g. }

• W4300890579 endingPage "45" @default.
• W4300890579 startingPage "1329" @default.
• W4300890579 abstract "To determine if photodynamic therapy with verteporfin (Visudyne; CIBA Vision Corp, Duluth, Ga) can safely reduce the risk of vision loss in patients with subfoveal choroidal neovascularization (CNV) caused by age-related macular degeneration (AMD).Two multicenter, double-masked, placebo-controlled, randomized clinical trials.Twenty-two ophthalmology practices in Europe and North America.Patients with subfoveal CNV lesions caused by AMD measuring 5400 microm or less in greatest linear dimension with evidence of classic CNV and best-corrected visual acuity of approximately 20/40 to 20/200.Six hundred nine patients were randomly assigned (2: 1) to verteporfin (6 mg per square meter of body surface area) or placebo (5% dextrose in water) administered via intravenous infusion of 30 mL over 10 minutes. Fifteen minutes after the start of the infusion, a laser light at 689 nm delivered 50J/cm2 at an intensity of 600 mW/cm2 over 83 seconds using a spot size with a diameter 1000 microm larger than the greatest linear dimension of the CNV lesion. At follow-up examinations every 3 months, retreatment with the same regimen was applied if angiography showed fuorescein leakage. The primary outcome was the proportion of eyes with fewer than 15 letters lost (approximately <3 lines of loss), adhering to an intent-to-treat analysis.In each group, 94% of patients completed the month 12 examination. Visual acuity, contrast sensitivity, and fluorescein angiographic outcomes were better in the verteporfin-treated eyes than in the placebo-treated eyes at every follow-up examination through the month 12 examination. At the month-12 examination, 246 (61%) of 402 eyes assigned to verteporfin compared with 96 (46%) of 207 eyes assigned to placebo had lost fewer than 15 letters of visual acuity from baseline (P<.001). In subgroup analyses, the visual acuity benefit (< 15 letters lost) of verteporfin therapy was clearly demonstrated (67% vs 39%; P<.001) when the area of classic CNV occupied 50% or more of the area of the entire lesion (termed predominantly classic CNV lesions), especially when there was no occult CNV. No statistically significant differences in visual acuity were noted when the area of classic CNV was more than 0% but less than 50% of the area of the entire lesion. Few ocular or other systemic adverse events were associated with verteporfin treatment, compared with placebo, including transient visual disturbances (18% vs 12%), injection-site adverse events (13% vs 3%), transient photosensitivity reactions (3% vs 0%), and infusion-related low back pain (2% vs 0%).Since verteporfin therapy of subfoveal CNV from AMD can safely reduce the risk of vision loss, we recommend verteporfin therapy for treatment of patients with predominantly classic CNV from AMD." @default.
• W4300890579 created "2022-10-04" @default.
• W4300890579 date "1999-10-01" @default.
• W4300890579 modified "2023-10-17" @default.
• W4300890579 title "Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group." @default.
• W4300890579 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10532441" @default.
• W4300890579 hasPublicationYear "1999" @default.
• W4300890579 type Work @default.
• W4300890579 citedByCount "226" @default.
• W4300890579 countsByYear W43008905792012 @default.
• W4300890579 countsByYear W43008905792014 @default.
• W4300890579 countsByYear W43008905792015 @default.
• W4300890579 countsByYear W43008905792016 @default.
• W4300890579 countsByYear W43008905792017 @default.
• W4300890579 countsByYear W43008905792018 @default.
• W4300890579 countsByYear W43008905792019 @default.
• W4300890579 countsByYear W43008905792020 @default.
• W4300890579 countsByYear W43008905792021 @default.
• W4300890579 countsByYear W43008905792022 @default.
• W4300890579 countsByYear W43008905792023 @default.
• W4300890579 crossrefType "journal-article" @default.
• W4300890579 hasConcept C118487528 @default.
• W4300890579 hasConcept C141071460 @default.
• W4300890579 hasConcept C142724271 @default.
• W4300890579 hasConcept C168563851 @default.
• W4300890579 hasConcept C204787440 @default.
• W4300890579 hasConcept C27081682 @default.
• W4300890579 hasConcept C2776403814 @default.
• W4300890579 hasConcept C2778257484 @default.
• W4300890579 hasConcept C2780248432 @default.
• W4300890579 hasConcept C2781148688 @default.
• W4300890579 hasConcept C2781359195 @default.
• W4300890579 hasConcept C71924100 @default.
• W4300890579 hasConceptScore W4300890579C118487528 @default.
• W4300890579 hasConceptScore W4300890579C141071460 @default.
• W4300890579 hasConceptScore W4300890579C142724271 @default.
• W4300890579 hasConceptScore W4300890579C168563851 @default.
• W4300890579 hasConceptScore W4300890579C204787440 @default.
• W4300890579 hasConceptScore W4300890579C27081682 @default.
• W4300890579 hasConceptScore W4300890579C2776403814 @default.
• W4300890579 hasConceptScore W4300890579C2778257484 @default.
• W4300890579 hasConceptScore W4300890579C2780248432 @default.
• W4300890579 hasConceptScore W4300890579C2781148688 @default.
• W4300890579 hasConceptScore W4300890579C2781359195 @default.
• W4300890579 hasConceptScore W4300890579C71924100 @default.
• W4300890579 hasIssue "10" @default.
• W4300890579 hasLocation W43008905791 @default.
• W4300890579 hasOpenAccess W4300890579 @default.
• W4300890579 hasPrimaryLocation W43008905791 @default.
• W4300890579 hasRelatedWork W1968078122 @default.
• W4300890579 hasRelatedWork W1974906048 @default.
• W4300890579 hasRelatedWork W1991009668 @default.
• W4300890579 hasRelatedWork W2012546470 @default.
• W4300890579 hasRelatedWork W2036520195 @default.
• W4300890579 hasRelatedWork W2281729836 @default.
• W4300890579 hasRelatedWork W2349219630 @default.
• W4300890579 hasRelatedWork W2377851881 @default.
• W4300890579 hasRelatedWork W2417525979 @default.
• W4300890579 hasRelatedWork W3031401955 @default.
• W4300890579 hasVolume "117" @default.
• W4300890579 isParatext "false" @default.
• W4300890579 isRetracted "false" @default.
• W4300890579 workType "article" @default.